MAY 29, 2018 4:30 PM PDT

Potential New Treatment to Block the Mechanism for Cancer Metastasis

WRITTEN BY: Mauri Brueggeman

In the last year, researchers have been looking closely at the cellular process of metastasis.  This spread of cancer within the body to distant sites makes therapeutic approaches more complicated.  Metastases remain difficult to treat for all cancer types, hence to examination into the process of metastasis to attempt to inhibit it before the process starts.  One area of focus is the perinucleolar region, which is usually referred to as the perinucleolar compartment (PNC).  This structure is located within the nucleus of a cancer cell.  Most of us learn about the nucleus and perhaps many also know the nucleolus.  The nucleus is where our DNA is stored.  The nucleolus is a small, usually spherical, structure within the nucleus; it is the site of rRNA transcription, processing, and ribosomal generation in transformed or various cancer tissues.  It is visualized microscopically when a cell is in interphase and is rarely found in normal cells. 

The critical component within the PNC identified recently is a compound called metarrestin.  According to the authors of the study, metarrestin disrupts the nucleolar structure and inhibits RNA polymerase I transcription via a translation elongation factor called eEF1A2.  Researchers found that metarrestin inhibited cancer cell invasion in vitro and in three separate mouse models of human cancer.  One of the mouse models had metastatic pancreatic cancer and survival was extended; the study also found that no organ toxicity or adverse effects were observed.

The newest study, published May 16, 2018, in the journal Science & Translational Medicine looked at pancreatic cancer effects in mouse models as described.  Additional research has been published in the past year with focus on other mouse models of cancer including lung and liver metastases of prostate cancer and breast cancer.  Liver histology reports included in the newest study show the metastatic tumors in liver tissue prior to treatment with metarrestin.  The after-treatment histology shows significant reduction in tumor presence.  Therefore, a novel approach to metastasis treatment could be to disrupt the protein-making apparatus within the metastatic cell itself.  If it cannot produce proteins and replicate itself, the cell fails to thrive and so growth stalls.

The group working on this research are collaborators from the National Institutes of Health, Northwestern University Feinberg School of Medicine, the National Center for Advancing Translational Sciences (NCATS)- Chemical Genomic Center, and the NCATS-Bridging Interventional Development Gaps program.  Together these professionals are gathering data on metarrestin needed to further its development as a clinical drug including application to the Federal Drug Administration for an Investigational New Drug status.  These are the steps needed to start the process of using metarrestin on patients as part of clinical trials.

Sources: Science & Translational Medicine, NIH National Center for Advancing Translational Sciences, Gynecologic Oncology, Cancer Research, Cold Spring Harbor Perspectives in Biology Journal,

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
NOV 22, 2019
Cancer
NOV 22, 2019
The cancerous fear of circular extrachromosomal DNA
New research published in Nature suggests that ring-shaped extrachromosomal DNA (ecDNA) is particularly abundant in tumor cells and plays a malicious role ...
DEC 04, 2019
Cancer
DEC 04, 2019
Photon up-conversion for new cancer treatments
Scientists from the University of California, Riverside and The University of Texas at Austin have made a breakthrough in materials science that has signif...
JAN 15, 2020
Clinical & Molecular DX
JAN 15, 2020
Laser microchip picks up cancer markers in urine
A future where patients no longer need to endure expensive, painful and complicated cancer tests could soon become a reality. Researchers have developed a...
FEB 04, 2020
Cancer
FEB 04, 2020
The role of SRR in colorectal cancer
Researchers from Osaka University have recently discovered a new function of the multifunctional enzyme entitled serine racemase (SRR). According to the te...
FEB 12, 2020
Genetics & Genomics
FEB 12, 2020
Vapers Have Epigenetic Alterations Like Those Seen in Smokers
The activity of genes can be altered with chemical tags that get added to the genome, so-called epigenetic modifications....
FEB 19, 2020
Immunology
FEB 19, 2020
Testing the Immune Response to Ovarian Cancer Treatment
There is a new diagnostic test for the deadliest form of gynecological cancer – ovarian cancer. Better tests mean better diagnostics, and better diag...
Loading Comments...